Rheumatoid Arthritis – Access & Reimbursement – Detailed, Expanded Analysis (US)

The availability of multiple targeted therapies with diverse mechanisms of action, including biologics / biosimilars and oral agents, along with conventional treatments, makes the rheumatoid arthritis (RA) market increasingly crowded. The expected launch of Galapagos / Gilead’s JAK inhibitor filgotinib, R-Pharm’s IL-6 inhibitor olokizumab, and GlaxoSmithKline's otilimab over the next few years will further fragment the market. Drug developers will undoubtedly face increasing challenges to gain favorable formulary positioning and physician uptake. In such scenarios, market access decisions for these therapies will play a key role in influencing rheumatologists’ prescribing behaviors in RA.

Questions Answered

  • How does the coverage of therapies for RA differ on MCOs’ largest commercial insurance plans? How do various cost-control measures impact the prescribing of current therapies for RA?
  • How do pharmacoeconomic / health economic outcomes data impact formulary decision making for therapies for RA?
  • What points of differentiation of new therapies for RA are/will be most compelling to rheumatologists and payers?
  • Do physicians expect to prescribe key emerging therapies, including filgotinib, olokizumab, and otilimab, to their RA patients? How do payers intend to reimburse these agents, and how will those decisions affect prescribing?

Content Highlights

Geography: United States.

Primary research: Survey of 96 U.S. rheumatologists and 30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs).

Key drugs covered: Actemra, Cimzia, Enbrel, filgotinib, Humira, infliximab, Kevzara, olokizumab, Olumiant, Orencia, otilimab, Rinvoq, Rituxan, Simponi, Xeljanz.

Reimbursement and contracting.

Access and prescribing.

Special topics.

Opportunities and challenges for emerging therapies.

Product Description

U.S. Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.

Table of contents

  • Rheumatoid Arthritis - Access & Reimbursement - Detailed, Expanded Analysis (US)
    • Access Reimbursement Rheumatoid Arthritis US December 2020

launch Related Market Assessment Reports